Share on StockTwits
 

Smith & Nephew (LON:SN)‘s stock had its “buy” rating reiterated by stock analysts at UBS AG in a report issued on Tuesday, AnalystRatingsNetwork reports. They currently have a GBX 1,000 ($16.43) target price on the stock. UBS AG’s price target would indicate a potential upside of 14.42% from the company’s current price.

SN has been the subject of a number of other recent research reports. Analysts at Goldman Sachs Group Inc. reiterated a “sell” rating on shares of Smith & Nephew in a research note to investors on Tuesday. Separately, analysts at Societe Generale reiterated a “sell” rating on shares of Smith & Nephew in a research note to investors on Monday. They now have a GBX 660 ($10.85) price target on the stock. Finally, analysts at Numis Securities Ltd reiterated an “add” rating on shares of Smith & Nephew in a research note to investors on Monday. They now have a GBX 1,000 ($16.43) price target on the stock, up previously from GBX 960 ($15.78). Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and six have given a buy rating to the stock. Smith & Nephew presently has an average rating of “Hold” and a consensus price target of GBX 847.73 ($13.93).

Smith & Nephew (LON:SN) traded down 1.35% during mid-day trading on Tuesday, hitting GBX 874.00. 2,063,395 shares of the company’s stock traded hands. Smith & Nephew has a 52 week low of GBX 692.592 and a 52 week high of GBX 897.00. The stock has a 50-day moving average of GBX 869.1 and a 200-day moving average of GBX 810.7. The company’s market cap is £7.857 billion.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.